Interview with the leaders at Amylyx, Maker of New FDA Approved ALS Drug Relyvrio

In this week’s Xtalks Life Science podcast episode, Ayesha and the team spoke with the co-founders and co-CEOs of Amylyx, Joshua Cohen and Justin Klee, and Amylyx’s General Manager of Canada Chris Aiello. Amylyx is a pharmaceutical company focused on the development of therapies for neurodegenerative diseases. On September 29th this year, Amylyx received FDA approval for its oral, fixed dose medication Relyvrio for the treatment of adults with amyotrophic lateral sclerosis (ALS). A few months earlier, the medication had received conditional approval in Canada, where it is marketed under the brand name Albrioza. To hear more about Relyvrio’s approval, including how the Ice Bucket Challenge for ALS helped in the drug’s development, and Amylyx’s continuing work in neurodegenerative diseases, tune into the episode. Read more at: Relyvrio Approved as ALS Treatment by the FDA For more life science and medical device content, visit the Xtalks Vitals homepage. Follow Us on Social Media Twitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured